Nutshell Therapeutics
- Biotech or pharma, therapeutic R&D
Nutshell is a clinical-stage biotech specialized in discovering and developing first-in-class and best-in-class allosteric small molecule therapies (activator or inhibitor) for undruggable or validated but challenging targets employing an (AIDD) AI-driven computational platform and fully integrated wet lab. Nutshell raised cumulatively $75 million (Series A) and is launching its Series B (cash runway through 2026/2027). IND for lead program cleared in the US (FPI expected in July) and IND application approval pending in China.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}